Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Open Orphan Plc (GB:HVO)
LSE:HVO
Holding GB:HVO?
Track your performance easily
HVO Stock Chart & Stats
Day’s Range― - ―
52-Week Range16.50p - 32.00p
Previous CloseN/A
Volume5.15K
Average Volume (3M)1.96M
Market Cap
£133.35M
Enterprise ValueN/A
Total Cash (Recent Filing)$93.50K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)8.2
Beta0.29
Next Earnings
Jun 25, 2025EPS EstimateN/A
Last Dividend Ex-Date
Apr 18, 2024Dividend Yield1.02%
Share Statistics
EPS (TTM)0.02
Shares Outstanding680,371,900
10 Day Avg. Volume2,924,764
30 Day Avg. Volume1,961,598
Standard Deviation0.21
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.07
Price to Cash Flow (P/CF)25.50
P/FCF Ratio89.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
35.00pPrice Target Upside81.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Open Orphan Plc News
PremiumCompany Announcements
JPMorgan Reduces Stake in hVIVO PLC Below Minimum Threshold
PremiumCompany Announcements
hVIVO PLC Sees Significant Shift in Voting Rights
PremiumCompany Announcements
hVIVO Expands European Footprint with Strategic Acquisition of CRS Units
PremiumCompany Announcements
hVIVO Achieves Record Revenue Growth in 2024 with Expanded Services
PremiumCompany Announcements
hVIVO to Lead Groundbreaking Phase 3 Trial for Whooping Cough VaccinePremiumCompany Announcements
hVIVO Secures Largest Contract Amidst Strategic Expansion
PremiumCompany Announcements
hVIVO Advances hMPV Challenge Model With Successful Pilot Study
PremiumCompany Announcements
hVIVO’s Landmark COVID-19 Study Published in Nature CommunicationsBulls Say, Bears Say
Bulls Say
Contract WinsHVIVO has signed a significant £11.5m contract with an existing top-tier pharma client to test its undisclosed antiviral candidate using hVIVO's established RSV human challenge study model.
Financial PerformanceThe business has delivered revenue and margin growth ahead of prior market expectations, along with building a new world-leading facility and diversifying its business.
Market PositionHCTs are increasingly recognized as key in infectious disease drug/vaccine development, with hVIVO being the market leader in this space.
Bears Say
Contract AnnouncementsThe market is concerned about the slowdown in HCT contract announcements and therefore 2025 guidance.
Share Price WeaknessRecent share price weakness is seen as a result of RFK Jr contagion, softer outlooks from CRO peers, and slower volume of contract announcements.
Stock Weakness FactorsKey factors driving the stock's weakness include the RFK Jr contagion effect, concerns on FY25 outlook, and lack of significant new contract announcements.
---
Options Prices
Currently, No data available
---
Ownership Overview
HVO FAQ
What was Open Orphan Plc’s price range in the past 12 months?
Open Orphan Plc lowest share price was 16.50p and its highest was 32.00p in the past 12 months.
What is Open Orphan Plc’s market cap?
Open Orphan Plc’s market cap is £133.35M.
When is Open Orphan Plc’s upcoming earnings report date?
Open Orphan Plc’s upcoming earnings report date is Jun 25, 2025 which is in 143 days.
How were Open Orphan Plc’s earnings last quarter?
Open Orphan Plc released its earnings results on Sep 10, 2024. The company reported 0.008p earnings per share for the quarter, beating the consensus estimate of N/A by 0.008p.
Is Open Orphan Plc overvalued?
According to Wall Street analysts Open Orphan Plc’s price is currently Undervalued.
Does Open Orphan Plc pay dividends?
Open Orphan Plc pays a Notavailable dividend of 0.2p which represents an annual dividend yield of 1.02%. See more information on Open Orphan Plc dividends here
What is Open Orphan Plc’s EPS estimate?
Open Orphan Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Open Orphan Plc have?
Open Orphan Plc has 680,371,900 shares outstanding.
What happened to Open Orphan Plc’s price movement after its last earnings report?
Open Orphan Plc reported an EPS of 0.008p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.787%.
Which hedge fund is a major shareholder of Open Orphan Plc?
Currently, no hedge funds are holding shares in GB:HVO
---
Open Orphan Plc Stock Smart Score
Company Description
Open Orphan Plc
Open Orphan PLC is a European-focussed, rare and orphan drug consulting services platform. The company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
---
HVO Stock 12 Month Forecast
Average Price Target
35.00p
▲(81.82% Upside)
Technical Analysis
Directa Plus
―
HUTCHMED (China) Limited
―
Legal & General
―
OptiBiotix Health
―
Scancell Holdings
―
Best Analysts Covering HVO
1 Year
1 Year Success Rate
1/6 ratings generated profit
1 Year Average Return
-20.78%
reiterated a buy rating 12 days ago
Copying James Orsborne's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -20.78% per trade.
---